shutterstock_1425740486_ii_studio

II Studio / Shutterstock.com

24 October 2019Big PharmaSaman Javed

Brazil accuses Gilead over 1,421.5% price hike of hep C drug

The Brazilian Federal Public Defender’s Office has filed a complaint against Gilead for hugely increasing the price of its hepatitis C drug since it gained patent protection.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

PTAB to review Minnesota patent after Gilead petition

2 June 2020 Gilead Sciences has persuaded the US Patent Trial and Appeal Board to review an antiviral patent owned by the University of Minnesota.

Antitrust HIV drugs case should be arbitrated, argue Gilead, BMS

16 February 2021 Gilead Sciences and Bristol-Myers Squibb have said that a suit alleging they were involved in a long-running scheme to block generic competition and keep HIV medication prices artificially high is “legally defective”.

article

Brazil rules 10-year patent term ‘unconstitutional’

11 May 2021 Brazil’s Supreme Court has ruled that the country’s ten-year patent term is unconstitutional.

More on this story

PTAB to review Minnesota patent after Gilead petition

2 June 2020 Gilead Sciences has persuaded the US Patent Trial and Appeal Board to review an antiviral patent owned by the University of Minnesota.

Antitrust HIV drugs case should be arbitrated, argue Gilead, BMS

16 February 2021 Gilead Sciences and Bristol-Myers Squibb have said that a suit alleging they were involved in a long-running scheme to block generic competition and keep HIV medication prices artificially high is “legally defective”.

article

Brazil rules 10-year patent term ‘unconstitutional’

11 May 2021 Brazil’s Supreme Court has ruled that the country’s ten-year patent term is unconstitutional.

More on this story

PTAB to review Minnesota patent after Gilead petition

2 June 2020 Gilead Sciences has persuaded the US Patent Trial and Appeal Board to review an antiviral patent owned by the University of Minnesota.

Antitrust HIV drugs case should be arbitrated, argue Gilead, BMS

16 February 2021 Gilead Sciences and Bristol-Myers Squibb have said that a suit alleging they were involved in a long-running scheme to block generic competition and keep HIV medication prices artificially high is “legally defective”.

article

Brazil rules 10-year patent term ‘unconstitutional’

11 May 2021 Brazil’s Supreme Court has ruled that the country’s ten-year patent term is unconstitutional.

More features

Bayer gains exclusive licence for heart drug in Japan

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

McGuireWoods expands team with ex-Novo Nordisk GC

Paul, Weiss swoops for senior duo from Weil, Gotshal

UPC bans Meril Life Sciences from selling infringing heart valve

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic

Kathi Vidal to rejoin previous firm as partner following USPTO departure

GSK triumphs in EPO appeal, revoking Pfizer patent